Herawati, Fauna and Fahmi, Eka Yuliantini and Pratiwi, Noer Aulia and Ramdani, Dewi and Jaelani, Abdul Kadir and Yulia, Rika and Andrajati, Retnosari (2019) Oral anti-tuberculosis (Anti-TB) drugs in the hospitals: a medication reconciliation needed. In: The 6th International Conference on Pharmacy and Advanced Pharmaceutical Sciences (ICPAPS 2019), 14-15 November 2019, Yogyakarta. (Submitted)
Preview |
PDF
Fauna_Oral anti-tuberculosis (Anti-TB) drugs in the hospitals_Abstrak.pdf Download (11kB) | Preview |
Abstract
Background: Available data from South Asia show one-third of TB deaths of the global burden. One-fifth among the treated cases had rifampicin-resistant TB. Four oral anti-tuberculosis drugs have been conceived to be the most effective ones to eradicate this bacterium Mycobacterium tuberculosis and to obviate the resistance organism. Nonetheless, the patients' adherence and medication discrepancies are obstacles to achieving the goal. This study aims to define the anti-tuberculosis drug in the hospitals to detect the discrepancies and the continuity of the tuberculosis treatment. Methods: This retrospective cross-sectional study is based on the medical records of adult patients (17-65 years old) with a diagnosis of pulmonary tuberculosis and hospitalized with the ICD-X code A15.0 (verified using sputum microscopy with or without culture) between January and December 2018. From 136 and 85 patients' medical records that observed, only thirty-five records from Hospital A and thirtythree records from Hospital B met the inclusion criteria. These two hospitals were a secondary care hospital with a total of 223 and 323 inpatient beds, respectively. Results: The most systemic anti-infective drugs were ceftriaxone (51.80 DDD/100 bed days) in Hospital A and isoniazid (50.08 DDD/100 bed days) in Hospital B. The number of rifampicin was less than isoniazid. The number of anti-tuberculosis drugs was 108.8 DDD/100 bed days (52.6%) in Hospital A and 194.50 DDD/100 bed days (100%) in Hospital B. Each patient received an average of 2 DDD/100 bed days. Conclusion: In the two-month intensive phase, each patient received four-drug fixeddose combination therapy and two-drug fixed-dose combination therapy in the fourmonth continuation phase. The medication discrepancies will threaten the antituberculosis drug effectiveness. Thus, medication reconciliation is needed to accomplish the TB-free world in 2035.
| Item Type: | Conference or Workshop Item (Paper) |
|---|---|
| Uncontrolled Keywords: | Defined daily dose (DDD), tuberculosis drug, medication reconciliation |
| Subjects: | R Medicine > RS Pharmacy and materia medica |
| Divisions: | Faculty of Pharmacy > Department of Pharmacy |
| Depositing User: | Ester Sri W. 196039 |
| Date Deposited: | 04 Nov 2019 03:28 |
| Last Modified: | 24 Mar 2021 16:14 |
| URI: | http://repository.ubaya.ac.id/id/eprint/36620 |
Actions (login required)
 |
View Item |
